Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease

E. Dreesen, F. Baert, D. Laharie, P. Bossuyt, Y. Bouhnik, A. Buisson, G. Lambrecht, E. Louis, B. Oldenburg, B. Pariente, M. Pierik, C.J. van der Woude, G. D'Haens, S. Vermeire, A. Gils

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)637-646.e11
Number of pages21
JournalClinical gastroenterology and hepatology
Volume18
Issue number3
DOIs
Publication statusPublished - 1 Mar 2020

Keywords

  • association
  • endoscopic healing
  • episodic treatment
  • immunogenicity
  • induction therapy
  • inflammatory-bowel-disease
  • management
  • multicenter
  • pharmacokinetics
  • scheduled maintenance treatment
  • serum infliximab
  • term efficacy
  • therapeutic drug monitoring
  • trough levels
  • INDUCTION THERAPY
  • EPISODIC TREATMENT
  • SCHEDULED MAINTENANCE TREATMENT
  • MULTICENTER
  • MANAGEMENT
  • SERUM INFLIXIMAB
  • TERM EFFICACY
  • INFLAMMATORY-BOWEL-DISEASE
  • Immunogenicity
  • Endoscopic Healing
  • Therapeutic Drug Monitoring
  • Pharmacokinetics
  • TROUGH LEVELS
  • ASSOCIATION

Cite this